| Pharmaceutical Information |
| Drug Name |
Verteporfin |
| Drug ID |
BADD_D02352 |
| Description |
Verteporfin, marketed as Visudyne, is a benzoporphyrin derivative. It is used as a photosensitizer in photodynamic therapy to eliminate abnormal blood vessels in wet form macular degeneration. Verteporfin accumulates in these abnormal blood vessels and, when stimulated by nonthermal red light with a wavelength of 693 nm in the presence of oxygen, produces highly reactive short-lived singlet oxygen and other reactive oxygen radicals, resulting in local damage to the endothelium and blockage of the vessels. |
| Indications and Usage |
For the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis syndrome. Verteporfin can also be used to destroy tumors. |
| Marketing Status |
Prescription |
| ATC Code |
S01LA01 |
| DrugBank ID |
DB00460
|
| KEGG ID |
D01162
|
| MeSH ID |
D000077362
|
| PubChem ID |
11980904
|
| TTD Drug ID |
D0I3XG
|
| NDC Product Code |
Not Available |
| Synonyms |
Verteporfin | BPD-MA | Benzoporphyrin Derivative Monoacid Ring A | Verteporphin | 18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester | BPD Verteporfin | Visudyne |
|
| Chemical Information |
| Molecular Formula |
C82H84N8O16 |
| CAS Registry Number |
129497-78-5 |
| SMILES |
CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C
)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C.CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C
(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)O)C(=C3C)CCC(=O)OC)C=C |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
